SECUADO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Secuado, and what generic alternatives are available?
Secuado is a drug marketed by Hisamitsu and is included in one NDA. There are six patents protecting this drug.
This drug has thirty-eight patent family members in nine countries.
The generic ingredient in SECUADO is asenapine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the asenapine profile page.
DrugPatentWatch® Generic Entry Outlook for Secuado
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be July 25, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SECUADO?
- What are the global sales for SECUADO?
- What is Average Wholesale Price for SECUADO?
Summary for SECUADO
| International Patents: | 38 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| Patent Applications: | 136 |
| Drug Prices: | Drug price information for SECUADO |
| What excipients (inactive ingredients) are in SECUADO? | SECUADO excipients list |
| DailyMed Link: | SECUADO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SECUADO
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for SECUADO
| Drug Class | Atypical Antipsychotic |
US Patents and Regulatory Information for SECUADO
SECUADO is protected by six US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SECUADO is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SECUADO
Patch
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patch
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
Patch and method for producing the same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
Patch
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-001 | Oct 11, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-003 | Oct 11, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-002 | Oct 11, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-001 | Oct 11, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-002 | Oct 11, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-002 | Oct 11, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Hisamitsu | SECUADO | asenapine | SYSTEM;TRANSDERMAL | 212268-003 | Oct 11, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for SECUADO
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| N.V. Organon | Sycrest | asenapine | EMEA/H/C/001177 Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. |
Authorised | no | no | no | 2010-09-01 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for SECUADO
When does loss-of-exclusivity occur for SECUADO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
China
Patent: 4487071
Estimated Expiration: ⤷ Sign Up
Patent: 4487072
Patent: Adhesive patch and production method therefor
Estimated Expiration: ⤷ Sign Up
Patent: 4507472
Patent: Adhesive patch
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 78298
Patent: TIMBRE ADHÉSIF ET SON PROCÉDÉ DE FABRICATION (ADHESIVE PATCH AND PRODUCTION METHOD THEREFOR)
Estimated Expiration: ⤷ Sign Up
Patent: 78299
Patent: TIMBRE ADHÉSIF (ADHESIVE PATCH)
Estimated Expiration: ⤷ Sign Up
Patent: 78300
Patent: PATCH
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 2014017593
Patent: 貼付剤及びその製造方法
Estimated Expiration: ⤷ Sign Up
Patent: 2014017594
Patent: 貼付剤
Estimated Expiration: ⤷ Sign Up
Patent: 2014017595
Patent: 貼付剤
Estimated Expiration: ⤷ Sign Up
Patent: 05741
Estimated Expiration: ⤷ Sign Up
Patent: 05742
Estimated Expiration: ⤷ Sign Up
Patent: 67707
Estimated Expiration: ⤷ Sign Up
Patent: 72418
Estimated Expiration: ⤷ Sign Up
Patent: 86011
Estimated Expiration: ⤷ Sign Up
Patent: 16199603
Patent: 貼付剤 (PATCHES)
Estimated Expiration: ⤷ Sign Up
Patent: 17025111
Patent: 貼付剤 (MEDICAL PATCH)
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 78299
Estimated Expiration: ⤷ Sign Up
Patent: 78300
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 78299
Estimated Expiration: ⤷ Sign Up
Patent: 78300
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2013476
Estimated Expiration: ⤷ Sign Up
Patent: 2013477
Estimated Expiration: ⤷ Sign Up
Patent: 2013478
Estimated Expiration: ⤷ Sign Up
Patent: 150036477
Patent: 첩부제 및 그 제조 방법 (ADHESIVE PATCH AND PRODUCTION METHOD THEREFOR)
Estimated Expiration: ⤷ Sign Up
Patent: 150036478
Patent: 첩부제 (ADHESIVE PATCH)
Estimated Expiration: ⤷ Sign Up
Patent: 150036479
Patent: 첩부제
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 32946
Estimated Expiration: ⤷ Sign Up
Patent: 33974
Estimated Expiration: ⤷ Sign Up
Patent: 81034
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 92170
Estimated Expiration: ⤷ Sign Up
Patent: 94771
Estimated Expiration: ⤷ Sign Up
Patent: 03748
Estimated Expiration: ⤷ Sign Up
Patent: 1410270
Patent: Adhesive patch and production method therefor
Estimated Expiration: ⤷ Sign Up
Patent: 1410271
Estimated Expiration: ⤷ Sign Up
Patent: 1410272
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SECUADO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2014017594 | ⤷ Sign Up | |
| Portugal | 2878300 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2014017595 | ⤷ Sign Up | |
| South Korea | 102013476 | ⤷ Sign Up | |
| Japan | WO2014017595 | 貼付剤 | ⤷ Sign Up |
| Japan | WO2014017594 | 貼付剤 | ⤷ Sign Up |
| Spain | 2633974 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SECUADO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0746317 | 10C0056 | France | ⤷ Sign Up | PRODUCT NAME: ASENAPINE; REGISTRATION NO/DATE: EU/1/10/640/001 20100901 |
| 0746317 | SPC/GB10/046 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ASENAPINE; REGISTERED: UK EU/1/10/640/001 20100901; UK EU/1/10/640/002 20100901; UK EU/1/10/640/003 20100901; UK EU/1/10/640/004 20100901; UK EU/1/10/640/005 20100901; UK EU/1/10/640/006 20100901 |
| 0746317 | C300461 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ASENAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MALEAAT; REGISTRATION NO/DATE: EU/1/10/640/001-006 20100901 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
